Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ProMIS Neurosciences Inc.

Get SEC filing alerts via email and in your feed for ProMIS Neurosciences Inc.

PMN

ProMIS Neurosciences Inc.

About ProMIS Neurosciences Inc.

Promis Neurosciences specializes in developing antibody therapies targeting misfolded proteins involved in neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's, and tauopathies. Utilizing proprietary computational platforms, it identifies disease-specific epitopes to generate highly selective monoclonal antibodies. Its pipeline includes candidates for Alzheimer’s disease, ALS, multiple system atrophy, and synucleinopathies, aiming to inhibit toxic protein propagation, reduce neurodegeneration, and improve patient outcomes through innovative biologic therapeutics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ProMIS Neurosciences Inc.

1
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports $8.2 Million Net Loss and Improved Cash Position in Latest Filing

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports $40.2 Million Operating Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports $11.6M Net Loss in Q3 2025 Amid Rising Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports $10.1 Million Net Loss in Q2 2025 Amid Rising R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports $7.3 Million Net Loss and Increased Operating Expenses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports $16.8 Million Operating Loss and Seeks Funding for Alzheimer's Drug Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ProMIS Neurosciences Inc. ProMIS Neurosciences Reports Turnaround in Q3 2024, Net Income of $9.3 Million

Via official filing (AI summary) | over 1 year ago | 0 comments